Entries |
Document | Title | Date |
20090005458 | Tapentadol for Treating Pain due to Osteoarthritis - The use of tapentadol for treating pain due to osteoarthritis. | 01-01-2009 |
20090012182 | Crystal forms of O-desmethylvenlafaxine succinate - Provided are crystalline forms of O-desmethylvenlafaxine succinate, methods for their preparation, and pharmaceutical composition thereof. | 01-08-2009 |
20090023814 | COMPOSITIONS AND METHODS HAVING MT1 RECEPTOR ACTIVITY - The present invention is directed to compositions and to methods comprising a composition comprising a therapeutically effective amount of a pharmaceutically active agent such as (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats and/or manages at least one condition having MT1 receptor activity and releases the pharmaceutically active agent, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a primary activity on the MT1 receptor such as, exhibiting at least five times more activity on the MT1 receptor compared with the MT2 receptor. | 01-22-2009 |
20090186947 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 07-23-2009 |
20090197969 | METHOD OF REDUCING BRAIN CELL DAMAGE OR DEATH - A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia/ischemia condition or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with a transient cerebral hypoxic and/or ischemic condition, or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, in addition to the continuous intravenous infusion dose, a bolus dose of methamphetamine is administered to the subject as soon as possible after onset of the condition or occurrence of the TBI event. | 08-06-2009 |
20090253802 | Therapeutic Agent for Treating liver Disease Containing 2-Amino-1,3-Propanediol Derivative as Active Ingredient, and Method for Treating Liver Disease - A novel therapeutic agent for organ disease, in particular, a therapeutic agent for liver disease is provided. | 10-08-2009 |
20090275664 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES - Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided. | 11-05-2009 |
20090312435 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. | 12-17-2009 |
20100010097 | Methods for treating mild cognitive impairment and alzheimer's disease - Mild cognitive impairment and Alzheimer's disease are treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. | 01-14-2010 |
20100022658 | Methods for treating cognitive impairment in humans - Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. | 01-28-2010 |
20100022659 | Methods and Compositions for the Treatment of CNS-Related Conditions - The invention provides methods and compositions for the treatment of dementia-related conditions, such as Parkinson's disease and Alzheimer's disease. | 01-28-2010 |
20100076087 | METHODS OF REDUCTION OF INTERPATIENT VARIABILITY - Disclosed herein are methods for the reduction of inter-patient variability of a drug, such as in one or more parameters including half-life (t | 03-25-2010 |
20100076088 | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Crystalline form IV of the compound of formula (I): | 03-25-2010 |
20100144886 | METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION - The present invention is directed to methods comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats, prevents and/or manages at least one condition having MT1 receptor, 5-HT2B receptor and L-type calcium channel activity and releases the (R)-verapamil, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a co-primary activity on the MT1 receptor, the 5-HT | 06-10-2010 |
20100160447 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 06-24-2010 |
20100227933 | PHARMACEUTICAL COMPOSITION FORMULATED FOR PRE-GASTRIC ABSORPTION OF MONOAMINE OXIDASE B INHIBITORS - The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing. | 09-09-2010 |
20100249242 | METHOD OF REDUCING NEURONAL CELL DAMAGE - The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and/or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and/or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxymethamphetamine, or a combination thereof. | 09-30-2010 |
20100280128 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain - The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain. | 11-04-2010 |
20100280129 | Method of Treating Pain Caused by Inflammation - A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amoung of a (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound or a physiologally acceptable salt thereof, such as the hydrochloride or citrate salt. | 11-04-2010 |
20100331425 | Tapentadol for Treating Pain due to Osteoarthritis - The use of tapentadol for treating pain due to osteoarthritis. | 12-30-2010 |
20110082214 | PROCESS FOR THE PREPARATION OF A SOLID DOSAGE FORM, IN PARTICULAR A TABLET, FOR PHARMACEUTICAL USE AND PROCESS FOR THE PREPARATION OF A PRECURSOR FOR A SOLID DOSAGE FORM, IN PARTICULAR A TABLET - Process for preparing a powder comprising the steps of providing at least one first component in liquid form at ambient temperature, providing at least one second component having a melting point or melting range in the range from above ambient temperature to below the degradation temperature of said first component, forming a homogenous liquid mixture comprising the at least one first component and the at least one second component by stirring and heating the mixture to or keeping the mixture at a temperature in the range from above the melting point or melting range of the second component and below the degradation temperature of the first component, transferring the liquid mixture to at least one spray congealing unit, spray congealing the mixture, and isolating the powder obtained upon spray congealing. | 04-07-2011 |
20110105621 | METHOD OF REDUCING BRAIN CELL DAMAGE, INFLAMMATION OR DEATH - A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, the dose is increased in response to a delay in administration. The invention also relates to a method for modulating cytokine expression within the brain to treat such conditions. | 05-05-2011 |
20110130465 | COATINGS FOR PREVENTION OF BIOFILMS - This invention is directed to a method to reduce microbial fouling on a surface. The present invention provides antifouling coatings similar to the protein glues secreted by marine mussels for adhesion to underwater substrates. | 06-02-2011 |
20110136915 | RAPID DISSOLUTION FORMULATION OF A CALCIUM RECEPTOR-ACTIVE COMPOUND - The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition. | 06-09-2011 |
20110257270 | DRUG FOR TREATMENT OF COLON CANCER - A first aspect of the invention provides a method for treating, preventing or ameliorating a hyperproliferative disease and/or disorder in a mammal comprising administering to the mammal a therapeutically effective amount of one or more compounds selected from the group consisting of compounds of Formula (1), (2), or a pharmaceutically acceptable salt or metabolite thereof. | 10-20-2011 |
20110263718 | PROCESS FOR THE PREPARATION OF O-DESMETHYLVENLAFAXINE - The present invention provides a convenient and efficient process for the preparation of O-desmethylvenlafaxine (ODV) or a salt thereof, comprising the reaction of venlafaxine, or a salt thereof, with a thiourea or a mixture of thioureas. | 10-27-2011 |
20110294898 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 12-01-2011 |
20110301245 | (R)-2-(3,4-DIMETHOXYPHENOL)-2-ISOPROPYL-6-AZAHEPTANITRIL FORMULAITONS, ANDTHE USE OF SUCH FORMULATIONS IN THE TREATMENT OF CONDITIONS MEDIATED BY THE SEROTONIN TRANSPORTER - Methods comprising administering compositions comprising therapeutically effective amounts of the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats or prevents at least one condition having serotonin transporter activity in a subject in need thereof, and releases the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative thereof, or a pharmaceutically acceptable salt thereof to exhibit an activity on the serotonin transporter. | 12-08-2011 |
20120004316 | TREATING IMPULSE CONTROL DISORDERS WITH CATECHOL-O-METHYL-TRANSFERASE INHIBITORS - The invention provides methods for treating impulse control disorders in patients with catechol-o-methyl-transferase inhibitors. The invention also provides methods for treating patients with obsessive compulsive disorders and substance addictions with catechol-o-methyl-transferase inhibitors. | 01-05-2012 |
20120004317 | Tapentadol for use in the treatment of irritable bowel syndrome - The invention relates to tapentadol for use in the treatment of Irritable Bowel Syndrome | 01-05-2012 |
20120041071 | TAPENTADOL FOR TREATING PAIN DUE TO OSTEOARTHRITIS - The use of tapentadol for treating pain due to osteoarthritis. | 02-16-2012 |
20120059066 | PHARMACEUTICAL SALTS - The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments. | 03-08-2012 |
20120077883 | TREATMENT OF TINNITUS AND ASSOCIATED AUDITORY DYSFUNCTIONS - The invention provides cyclobenzaprine for use in the treatment of tinnitus and related auditory dysfunctions by oral administration as tablets, capsules, powder or a solution or by parenteral administration of cyclobenzaprine through intramuscular, intravenous, subcutaneous or intrathecal injection, or infusion, preferably in an amount from 15 to 45 mg/day, preferably in a long-term treatment over 2 or 8 weeks or more. | 03-29-2012 |
20120083535 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 04-05-2012 |
20120095105 | INHIBITORS OF COGNITIVE DECLINE - Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention. | 04-19-2012 |
20120129945 | INHIBITORS OF COGNITIVE DECLINE - Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention. | 05-24-2012 |
20120142785 | METHODS FOR TREATING ALZHEIMER'S DISEASE - Alzheimer's disease is treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. | 06-07-2012 |
20120214876 | Seizure and Migraine Treatments using the Bone Homeostasis Drug Cinacalcet - A novel pathogenesis underlying certain types of seizures and migraines is disclosed and the validated set of premises presented enable the deductive conclusion to be made that drugs that reduce the amount of calcium ions (Ca++) released from bone reduce seizure and migraine risk. The premises validated as true in the specifications include:
| 08-23-2012 |
20120225950 | Semisolid Aqueous Pharmaceutical Composition Containing Tapentadol - A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof. | 09-06-2012 |
20120225951 | Parenteral Administration of Tapentadol - An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4. | 09-06-2012 |
20120232159 | Methods and Compositions for Treating Depression using Cyclobenzaprine - The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising cyclobenzaprine, alone, or in combination with an antidepressant drug. | 09-13-2012 |
20120264828 | POLYMORPHIC FORMS OF O-DESMETHYL-VENLAFAXINE SUCCINATE - The present invention discloses polymorphic forms of O-desmethyl-venlafaxine succinate and processes for the preparation thereof. | 10-18-2012 |
20120270948 | POLYMORPHISIMS IN THE HUMAN CYP2D6 GENE PROMOTER REGION AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to intermediate metabolization of drugs are described. In addition, kits comprising oligonucleotides hybridizing to the CYP2D6 promoter and/or being capable of being extended into this region useful for diagnosing subjects that are ultrarapid or intermediate metabolizer of drugs are provided. | 10-25-2012 |
20120270949 | MELT-GRANULATED CINACALCET - The invention relates to an intermediate obtainable by the melt-extrusion of (i) cinacalcet or a pharmaceutically acceptable salt thereof with (ii) a matrix former, and oral dosage forms, especially tablets containing the intermediates of the invention. The invention further relates to a method of preparing the tablets of the invention. Finally, the invention relates to the use of a matrix former and a wicking agent for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 10-25-2012 |
20120277319 | Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety - The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety. | 11-01-2012 |
20120302643 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 11-29-2012 |
20120309841 | Method of Inhibiting Chronification of Pain - The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine. | 12-06-2012 |
20120309842 | PROCESSES FOR THE PREPARATION OF CINACALCET - The present invention provides processes and intermediates for preparing cinacalcet base and pharmaceutically acceptable salts thereof. | 12-06-2012 |
20130030056 | METHODS OF DELIVERING PHARMACEUTICAL AGENTS - Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject. | 01-31-2013 |
20130053448 | Therapeutic Regimens - This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol. | 02-28-2013 |
20130059917 | MODIFIED RELEASE DOSAGE FORM COMPRISING DESVENLAFAXINE OR SALTS THEREOF - The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed. | 03-07-2013 |
20130085184 | Intrathecal or Epidural Administration of 3-[(1S,2S)-3-(Dimethylamino)-1-Ethyl-2-Methylpropyl]Phenol - The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any non-central nervous system mediated systemic effect in the subject. In particular, the present invention relates to a method of administering 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes. | 04-04-2013 |
20130116333 | SOLID TAPENTADOL IN NON-CRYSTALLINE FORM - The invention relates to solid tapentadol in non-crystalline form together with a surface stabiliser in the form of a stable intermediate. In the intermediate of the invention, tapentadol is preferably present in amorphous form or in the form of a solid solution. The invention further relates to methods of producing tapentadol in a solid, non-crystalline form and to pharmaceutical formulations containing solid, non-crystalline tapentadol. | 05-09-2013 |
20130116334 | Treatment of Irritable Bowel Syndrome - A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol. | 05-09-2013 |
20130210924 | Dosage Regimen of Diaryl Sulfide Derivatives - A compound of formula (I) wherein X is O, S, SO or SO | 08-15-2013 |
20130231395 | METHODS FOR TREATING ALZHEIMER'S DISEASE - Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound. | 09-05-2013 |
20130237608 | Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol - A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours. | 09-12-2013 |
20130281542 | SELEGILINE TRANSDERMAL SYSTEM - Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing selegiline base for the treatment of depression, Parkinson's disease, and other nervous system conditions. | 10-24-2013 |
20130303623 | THERMOFORMED, TAMPER-RESISTANT PHARMACEUTICAL DOSAGE FORM CONTAINING ZINC - A thermoformed, tamper-resistant pharmaceutical dosage form comprises:
| 11-14-2013 |
20130317114 | Hydroxylated Tricyclic Compounds - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer. | 11-28-2013 |
20130338232 | METHOD OF REDUCING BRAIN CELL DAMAGE, INFLAMMATION OR DEATH - A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, the dose is increased in response to a delay in administration. The invention also relates to a method for modulating cytokine expression within the brain to treat such conditions. | 12-19-2013 |
20140011886 | Crystalline Forms of (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 01-09-2014 |
20140024720 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLOBENZAPRINE SUITABLE TO INTRANASAL ADMINISTRATION - A pharmaceutical composition, containing as active principle cyclobenzaprine hydrochloride, 3-(5H-dibenzo[a,d]cyclo-epten-5-yliden)-N,N-dimethyl-1-propanamine hydrochloride, in form suitable to be administered by itranasal route, is described. Said pharmaceutical composition allows a remarkable absorption rapidity of the active principle, does not undergo the first hepatic passage, has an excellent tolerability with low tonicity formulations and does not show any contraindication in the short period administrations. | 01-23-2014 |
20140171515 | COMPOSITIONS AND METHODS FOR TRANSMUCOSAL ABSORPTION - The invention provides compositions and methods for administering compounds for transmucosal absorption. The compositions and methods have a number of surprising pharmacokinetic benefits over oral administration of a compound. | 06-19-2014 |
20140194524 | Methods for Treating Alzheimer's Disease - Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound. | 07-10-2014 |
20140213658 | TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof. | 07-31-2014 |
20140221499 | NOVEL RODENT CONTROL AGENTS AND USES THEREOF - Provided herein is method for controlling a rodent. The method comprises contacting the rodent with a compound which is a ligand for an olfactory trace amine associated receptor (TAAR) or a composition comprising such a molecule. The compound can be a biogenic amine. | 08-07-2014 |
20140235728 | POLYMORPHS OF 4-[2-DIMETHYLAMINO-1-(1-HYDROXYCYCLOHEXYL)ETHYL]PHENYL 4-METHYLBENZOATE HYDROCHLORIDE, METHODS OF PREPARING THE SAME AND USE OF THE SAME - The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same. | 08-21-2014 |
20140256823 | TRANSMUCOSAL DRUG DELIVERY SYSTEM - Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH. | 09-11-2014 |
20140296346 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 10-02-2014 |
20140303257 | Use of EDG Receptor Binding Agents in Cancer - Provided is a method for treating solid tumors, e.g tumor invasiveness, and particularly inhibiting or controlling deregulated angiogenesis, using a sphingosine-1-phosphate receptor agonist, optionally in combination with a chemotherapeutic agent. The invention also comprises a combination of a sphingosine-1-phosphate receptor agonist with a chemotherapeutic agent. | 10-09-2014 |
20140323580 | PHENTERMINE LIQUID DOSAGE FORM - A pharmaceutical composition liquid dosage form of phentermine is provided, the dosage form including a liquid carrier and suspended or dissolved therein one or more pharmaceutically active ingredient selected from phentermine, salts and bases thereof. Also provided is a method of administering phentermine to an obese patient in need thereof and for appetite suppression or related conditions. | 10-30-2014 |
20140323581 | TRANSCRIPTOME WIRING ANALYSIS IN PARKINSON'S DISEASE AND USES THEREOF - The invention is directed to methods to identify predisposition or risk to develop Parkinson's disease, methods to identify agents which have therapeutic effect on Parkinson's disease, and methods to determine the therapeutic effect of an agent in a subject suffering from Parkinson's disease, and to kits and reagents for carrying out the methods of the invention. | 10-30-2014 |
20140329908 | Method For The Treatment of Dravet Syndrome - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 11-06-2014 |
20140336264 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE - The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol. | 11-13-2014 |
20140336265 | Dosage Regimen of Diaryl Sulfide Derivatives - A compound of formula I: | 11-13-2014 |
20140343160 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that they accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 11-20-2014 |
20140343161 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 11-20-2014 |
20140343162 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 11-20-2014 |
20140350118 | TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof. | 11-27-2014 |
20140371324 | INHIBITORS OF COGNITIVE DECLINE - Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention. | 12-18-2014 |
20150018426 | Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety - The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety. | 01-15-2015 |
20150045444 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 02-12-2015 |
20150065581 | METHODS AND COMPOSITIONS FOR TREATING FATIGUE ASSOCIATED WITH DISORDERED SLEEP USING VERY LOW DOSE CYCLOBENZAPRINE - The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment. | 03-05-2015 |
20150290148 | METHOD OF REDUCING BRAIN CELL DAMAGE, INFLAMMATION OR DEATH - A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, the dose is increased in response to a delay in administration. The invention also relates to a method for modulating cytokine expression within the brain to treat such conditions. | 10-15-2015 |
20150352062 | METHODS AND SYSTEMS FOR TREATING OVERWEIGHT INDIVIDUALS - A system for inducing weight loss in an individual includes a collection having plurality of dose units therein. Each dose unit includes a first dose of phentermine or a second dose of phentermine. The first dose is greater than the second dose, and the collection includes at least one first dose and at least one second dose. | 12-10-2015 |
20160022608 | Therapeutic Regimens - This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol. | 01-28-2016 |
20160022609 | METHODS FOR TREATING CHRONIC PAIN USING A COMBINATION OF BUPROPION ((.+-.)-2-(TERT-BUTYLAMINO)-1-(3-CHLOROPHENYL)PROPAN-1-ONE) AND PHENTERMINE (2-METHYL-1-PHENYLPROPAN-2-AMINE) - Methods for treating chronic pain are disclosed. More specifically, methods for treating chronic pain include administering a composition including bupropion and phentermine Methods for treating neuropathic pain and for treating nociceptive pain are further disclosed. | 01-28-2016 |
20160030576 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE - The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol. | 02-04-2016 |
20160067197 | TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof. | 03-10-2016 |
20160074342 | Titration of Tapentadol - The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a03-17-2016 | |
20160122287 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 05-05-2016 |
20160136112 | COMPOSITION COMPRISING TAPENTADOL IN A DISSOLVED FORM - The present invention relates to a composition comprising tapentadol in a dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising tapentadol in a dissolved form and to the corresponding process of producing an oral dosage form containing the composition of the invention. Finally, the invention relates to the use of a saturated tapentadol solution for the preparation of a solid oral dosage form. | 05-19-2016 |
20160137588 | INHIBITORS OF COGNITIVE DECLINE - Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention. | 05-19-2016 |
20160143863 | DISINTEGRANT FREE COMPOSITION OF CINACALCET - The present invention relates to pharmaceutical composition of Cinacalcet or a pharmaceutically acceptable salt thereof comprising diluents, binders and lubricants, wherein said composition is substantially free of disintegrant. It further relates to process for preparing such compositions. | 05-26-2016 |
20160151309 | PROLONGED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)PHENOL | 06-02-2016 |
20160158166 | METHODS OF REDUCING BRAIN CELL APOPTOSIS - A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia/ischemia condition or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with a transient cerebral hypoxic and/or ischemic condition, or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, in addition to the continuous intravenous infusion dose, a bolus dose of methamphetamine is administered to the subject as soon as possible after onset of the condition or occurrence of the TBI event. | 06-09-2016 |
20160374964 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Described herein are antimicrobial compounds identified via a high-throughput screen to identify compounds that produce anucleate cells in | 12-29-2016 |
20220133651 | TREATMENT OF PITT-HOPKINS SYNDROME - The present invention relates to amitriptyline or a pharmaceutically acceptable sale thereof, for use in the treatment of Pitt-Hopkins syndrome. | 05-05-2022 |
20220133652 | A FORMULATION FOR IMPROVING SEIZURE CONTROL - Described herein is a method of improving seizure control in a patient experiencing uncontrolled seizures persisting 10 minutes or more, comprising administering fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, at a dose of from 0.2 to 1.2 m/kg/day for a period of about 12 hours to about 7 days to a patient having been put into a therapeutic, medically-induced coma via a general anesthetic; and after about 12 hours to about 7 days, weaning the patient from the general anesthetic and assessing whether the seizure control has improved as compared to a pre-treatment time point. The patient experiencing seizures may have epilepsy or epileptic encephalopathy that has led to established status epilepticus (SE), refractory status epilepticus (RSE) or super-refractory status epilepticus (SRSE). | 05-05-2022 |